BRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy

Reuters

Feb 09

BRIEF-<a href="https://laohu8.com/S/SLDB">Solid Biosciences</a> Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy

Feb 9 (Reuters) - Solid Biosciences Inc SLDB.O:

SOLID BIOSCIENCES ANNOUNCES POSITIVE FEEDBACK FROM TYPE C MEETING WITH FDA FOR SGT-003 GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY
SOLID BIOSCIENCES INC: COMPANY PLANS FOR ADDITIONAL MEETINGS WITH FDA IN 1H 2026
SOLID BIOSCIENCES INC - ALIGNS WITH FDA ON PHASE 3 TRIAL DESIGN
SOLID BIOSCIENCES INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2026
SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9

Source text: ID:nGNX4m8RNK

Further company coverage: SLDB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610590926"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610590926\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610590926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610590926","market":"nz","top_or_hot":-1,"title":"BRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy</title></head><body><p><span>Feb 9 (Reuters)</span><span> - </span>Solid Biosciences Inc <span>SLDB.O</span>:</p><ul><li><p>SOLID BIOSCIENCES ANNOUNCES POSITIVE <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM TYPE C MEETING WITH FDA FOR SGT-003 GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY</p></li><li><p>SOLID BIOSCIENCES INC: COMPANY PLANS FOR ADDITIONAL MEETINGS WITH FDA IN 1H 2026</p></li><li><p>SOLID BIOSCIENCES INC - ALIGNS WITH FDA ON PHASE 3 TRIAL DESIGN</p></li><li><p>SOLID BIOSCIENCES INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2026</p></li><li><p>SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9</p></li></ul><p>Source text: <span>ID:nGNX4m8RNK</span></p><p>Further company coverage: <span>SLDB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-09 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy</title></head><body><p><span>Feb 9 (Reuters)</span><span> - </span>Solid Biosciences Inc <span>SLDB.O</span>:</p><ul><li><p>SOLID BIOSCIENCES ANNOUNCES POSITIVE <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM TYPE C MEETING WITH FDA FOR SGT-003 GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY</p></li><li><p>SOLID BIOSCIENCES INC: COMPANY PLANS FOR ADDITIONAL MEETINGS WITH FDA IN 1H 2026</p></li><li><p>SOLID BIOSCIENCES INC - ALIGNS WITH FDA ON PHASE 3 TRIAL DESIGN</p></li><li><p>SOLID BIOSCIENCES INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2026</p></li><li><p>SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9</p></li></ul><p>Source text: <span>ID:nGNX4m8RNK</span></p><p>Further company coverage: <span>SLDB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAB5ZZWL:1","article_id":"2610590926","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610590926","pubTimestamp":1770649075,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular DystrophyFeb 9 (Reuters) - Solid Biosciences Inc SLDB.O:SOLID BIOSCIENCE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLDB":"Solid Biosciences"},"translate_title":"简介-Solid Biosciences宣布与FDA就Sgt-003基因治疗杜氏肌营养不良症的C型会议获得积极反馈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLDB":0.9},"content_text":"BRIEF-Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular DystrophyFeb 9 (Reuters) - Solid Biosciences Inc SLDB.O:SOLID BIOSCIENCES ANNOUNCES POSITIVE FEEDBACK FROM TYPE C MEETING WITH FDA FOR SGT-003 GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHYSOLID BIOSCIENCES INC: COMPANY PLANS FOR ADDITIONAL MEETINGS WITH FDA IN 1H 2026SOLID BIOSCIENCES INC - ALIGNS WITH FDA ON PHASE 3 TRIAL DESIGNSOLID BIOSCIENCES INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2026SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9Source text: ID:nGNX4m8RNKFurther company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}